Lipid-lowering drugs affect lung cancer risk via sphingolipid metabolism: a drug-target Mendelian randomization study.

Front Genet · 2023 · PMC10687161 · PMID 38034491

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

did not reach statistical significancep = 0.072so close (0.05 < p ≤ 0.1)

Although APOB inhibition increased the plasma neutral ceramidase level via LDL reduction, it did not reach statistical significance after correction (OR 1.25, 95% CI 1.03–1.51, p = 0.072).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.